Table 1.
Outcomes in DLBCL-RS with standard CIT
| Study and years of patient recruitment | Regimen | n | Median age (years) | Results | ||
|---|---|---|---|---|---|---|
| ORR | CRR | Median OS | ||||
| Anthracycline-containing regimens | ||||||
| Langerbeins et al16 (2003-2008) | R-CHOP | 15 | 69 (N/A) | 67% | 7% | 21 months |
| Dabaja et al17 (published 2000) | HyperCVXD | 29 | 61 (36-75) | 41% | 38% | 10 months |
| Tsimberidou et al18 (1999-2001) | Rituximab and GM-CSF with alternating hyperCVAD and MTX/cytarabine | 30 | 59 (27-79) | 43% | 18% | 8.5 months |
| Rogers et al19 (2006-2014) | R-EPOCH | 46 | 67 (38-83) | 39% | N/A | 5.9 months |
| Platinum-containing regimens | ||||||
| Tsimberidou et al20 (2004-2006) | OFAR1 | 20 | 59 (34-77) | 50% | 20% | 8 months |
| Tsimberidou et al21 (2007-2010) | OFAR2 | 35 | 63 (40-81) | 43% | 8.6% | 6.6 months |
| Fludarabine-containing regimens | ||||||
| Giles et al22 (1992-1996) | PFA or CFA | 12 | 59 (49-74) | 45% | N/A | 17 months |
| Tsimberidou et al23 (1997-2001) | FACPGM | 15 | 62 (42-74) | 5% | 5% | 2.2 months |
CFA, cyclophosphamide-fludarabine-arabinosyl cytosine; FACPGM, fludarabine–cytarabine–cyclophosphamide–cisplatin–GM-CSF; GM-CSF, granulocyte-macrophage colony-stimulating factor; HyperCVAD, fractionated cyclophosphamide-vincristine-liposomal daunorubicin- dexamethasone; MTX, methotrexate; N/A, not available; OFAR, oxaliplatin-fludarabine-cytarabine-rituximab; PFA, cisplatin, fludarabine, cytarabine.